<DOC>
	<DOCNO>NCT00202397</DOCNO>
	<brief_summary>Cerebellar disorder often disable symptomatic therapy limit option partially effective . It seem therefore appropriate search additional approach . Purkinje cell sole output cerebellar cortex : project inhibitory signal deep cerebellar nucleus ( DCN ) , critical role cerebellar function motor performance . DCN neuron fire spontaneously absence synaptic input Purkinje neuron modulation DCN response Purkinje input believe responsible coordination movement . Recent evidence support notion increase DCN excitability may important step development cerebellar ataxia point underlie molecular mechanism : inhibition small-conductance calcium-activated potassium ( SK ) channel , cause increase fire frequency DCN , correlate cerebellar ataxia . The rationale present project SK channel opener , riluzole , may beneficial effect cerebellar ataxia . The researcher propose perform pilot study investigate safety efficacy riluzole , approve treatment amyotrophic lateral sclerosis , symptomatic approach patient chronic cerebellar ataxia .</brief_summary>
	<brief_title>Effect Riluzole Symptomatic Approach Patients With Chronic Cerebellar Ataxia</brief_title>
	<detailed_description>Forty patient chronic cerebellar ataxia enrol double-bind , randomize , placebo-controlled trial . By central randomisation , patient take 50 mg riluzole placebo twice daily 8 week . Electrocardiogram routine laboratory test pregnancy test perform drug administration , 4 week treatment end study ( 8 week treatment ) . At time point International Cooperative Ataxia Rating Scale ( ICARS ) pharmacological assessment cerebellar syndrome administer two group ( riluzole placebo ) patient . To guarantee evaluation result blind condition , neurologist evaluate ICARS score different deal randomisation follow-up patient .</detailed_description>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Spinocerebellar Degenerations</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>Patients cerebellar degeneration ( heredoataxias , sporadic idiopathic ataxia , multiple system atrophy type C ) Patients meet McDonald criterion probable definite multiple sclerosis ( MS ) chronic cerebellar ataxia ( acute cerebellar ataxia due relapse ) Age 18 80 year Ataxia due disease Acute cerebellar ataxia Use drug chronic ataxia Serious concomitant illness ( cardiac arrhythmia , haematological hepatic disease ) Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>cerebellar ataxia</keyword>
	<keyword>deep cerebellar nucleus ( DCN )</keyword>
	<keyword>small-conductance calcium-activated potassium ( SK ) channel</keyword>
	<keyword>riluzole</keyword>
	<keyword>Sporadic ataxia</keyword>
	<keyword>Multiple system atrophy type C</keyword>
</DOC>